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ABSTRACT
Objectives: The purpose of this study was to identify clinical risk factors for the recurrence of ovarian endometrioma after 
ovarian cystectomy in Korean women with long-term postoperative medical therapy. 
Material and Methods: A total of 134 patients who were surgically treated for endometriotic cysts at Pusan National Uni-
versity Hospital were included in this retrospective study. All patients received long-term postoperative medical treatment 
for at least 12 months after the first-line conservative surgery. Several epidemiologic variables were analyzed as possible 
risk factors for recurrence. Endometrioma recurrence was considered when a cystic mass was observed on transvaginal or 
transrectal sonography. Statistical analysis was performed using independent t-tests for parametric continuous variables. 
Results: The mean follow-up period for the 134 patients was 56.5 ± 14.3 months (range, 36–120 months) and the mean dura-
tion of the medical therapy was 17.9 ± 17.3 months (range, 12–120 months). The overall recurrence rate was 35/134 (26.12%). 
Our univariate analysis showed statistically significant differences between the recurrent and non-recurrent groups in 
terms of weight (P = 0.013), body mass index (P = 0.007), age at the time of surgery (P = 0.013), the diameter of the largest 
cyst (P = 0.001), the presence of dysmenorrhea (P < 0.0001), and postoperative pregnancy (P = 0.016). Multivariate analy-
sis showed that body mass index (OR 1.153, 95% CI 1.003–1.326, P = 0.046), age at the time of surgery (OR 0.924, 95% CI 
0.860–0.992, P = 0.029), and presence of dysmenorrhea (OR 12.226, 95% CI 3.543–42.188, P < 0.0001) were significantly 
correlated with the recurrence of endometrioma.
Conclusions: We found that patients with dysmenorrhea after surgery, and a younger age of the patient at the time of surgery 
were the highest risk factors associated with the recurrence of endometrioma, despite long-term postoperative medication.
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INTRODUCTION
Endometriosis is characterized by the growth of en-
dometrial tissue outside the uterine cavity, which induces 
a chronic inflammatory reaction [1]. Ovarian endometrioma 
is observed in approximately 20–40% of women with endo-
metriosis [2]. Endometriosis is predominant in women of re-
productive age with a prevalence of 10 to 15% [3, 4]. Several 
theories for this have been suggested, including retrograde 
menstruation, altered immunity, coelomic metaplasia, and 
metastatic spread. However, the pathogenesis of endo-
metriosis is still unknown. [5]. The treatment of choice for 
endometrioma is usually surgery because of the limited ef-
ficacy of medication and the possibility of malignancy [6, 7]. 
However, vigorous debates about surgical approaches to 
the treatment of ovarian endometrioma in relation to ovar-
ian reserve are ongoing [8]. 
The recurrence of endometrioma is one of the most 
important unresolved problems in the management of en-
dometriosis. There have been two hypotheses that seek to 
explain the underlying pathophysiology of endometrioma 
recurrence: growth from residual lesions, or the develop-
ment of retrograde menstruation after surgery [9]. 
Recently, Seo et al. suggested the young age of women 
undergoing treatment as a risk factor for endometrioma recur-
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rence [10]. Moreover, there are some studies on risk factors 
for recurrence. The patient’s age, postoperative pregnancy, 
the severity of endometriosis and the size of the ovarian cyst 
were proposed as related factors in the recurrence of endo-
metrioma among Japanese women [11–14]. However, there 
are only a few studies conducted in Korea. Lee et al. reported 
the risk factors associated with recurrence of endometrioma in 
patients younger than 20 years; and Kim et al. reported risk fac-
tors in patients with a history of two or more previous surgical 
managements for endometriosis [15, 16]. However, these stud-
ies included heterogeneous patient groups, which combined 
all the patients with or without postoperative medical therapy.
Because endometrioma is widely reported to have 
a high recurrence rate after surgery, some clinicians prefer to 
prescribe long-term use of oral contraceptives or progestin 
in order to prevent recurrence, and long-term postopera-
tive medication has become the standard therapy for the 
women who wish to conceive in the future [17]. Therefore, 
it would be valuable to investigate the risk factors that are 
related to endometrioma recurrence in patients receiving 
long-term medical therapy.
The purpose of our study was to analyze the risk fac-
tors associated with endometrioma recurrence among 
Korean patients receiving long-term medical therapy to 
prevent recurrence.
MATERIAL AND METHODS
1. Patients 
Our study was a retrospective analysis of the records of 
patients with an histologic diagnosis of endometrioma who 
had long-term medical therapy. The study group was com-
prised of 134 patients selected from 334 patients who had 
been surgically treated by a single surgeon at Pusan National 
University Hospital between January 2008 and December 
2014. Patients with the following histories were included 
in this study: 1). surgical treatment of endometriotic cysts; 
2). final diagnosis of endometriosis confirmed by pathologi-
cal findings; and 3). postoperative medical treatment for at 
least 12 months. Exclusion criteria were as follows: 1). discon-
tinuation of medical treatment for a period of more than one 
month for any reason; 2). previous hysterectomy and/or 
bilateral oophorectomy for therapeutic purpose for endo-
metriosis or any other illness; 3). diagnosis of menopause, 
post-operatively or during follow-ups; and 4). any medical 
history that could influence medication metabolism. The 
patients underwent clinical postoperative follow-ups at 
intervals of three to six months. In each follow-up visit, 
clinical data were recorded after a transvaginal ultrasound, 
pelvic examination and serum CA-125 test.
2. Endometrioma recurrence 
All patients had a transvaginal ultrasound scan adminis-
tered by an experienced sonographer and using the Interna-
tional Ovarian Tumor Analysis (IOTA) terms and definitions 
to describe the ultrasound findings [18]. Endometrioma 
recurrence was defined by typical features, such as the pres-
ence of a ground glass-shaped cyst with a homogenous 
low-level echogenicity. 
3. Epidemiological and clinical risk factors
Medical chart reviews and patients’ interview records 
were used to collect patient information and calculate 
demographics such as weight, height, body mass index 
(BMI), parity, age at the time of surgery, previous history 
of cesarean section, number of previous surgeries, time to 
recurrence, unilateral or bilateral involvement, presence of 
cul-de-sac adhesions, the diameter of the largest cyst, the 
type of surgical management (laparotomy or laparoscopy), 
postoperative medication, the presence of dysmenorrhea, 
postoperative pregnancy in patients with postoperative 
medication of 12 months of more, total revised ASRM 
scores, and stage of the disease. The stage of the disease 
was defined according to the revised American Society for 
Reproductive Medicine (rASRM) scale as stage I (minimal), 
stage II (mild), stage III (moderate), and stage IV (severe) [19].
4. Statistical analysis
Comparisons of continuous data between two groups 
were performed with the use of an independent t-test or 
Wilcoxon rank-sum test (Mann-Whitney-Wilcoxon test), and 
categorical data were analyzed using the chi-square test 
or Fisher’s exact test. Univariate and multivariate analyses 
were performed using multiple logistic regression analysis, 
to evaluate the possible risk factors for endometrial cyst 
recurrence. Statistical analysis was performed using SAS 
9.3 for Windows (SAS Institute, Cary, NC, USA). Statistical 
significance was set at P < 0.05.
RESULTS
The mean follow-up period for the one hundred and 
thirty-four patients in our study was 56.5 months (range, 
36–120 months), and the median duration of medical ther-
apy was 12 months (range, 12–120 months). The clinical 
characteristics of the patients with, and without, the recur-
rence of endometrioma are shown in Table 1. From a total of 
134 consecutive patients who were treated with laparoscopy 
and/or laparotomy, endometrioma recurred in 35 patients, 
and the overall recurrence rate was 26.1%. 
Weight, BMI, age at the time of surgery, size of endome-
trioma, rASRM score and stage, the presence of dysmenor-
rhea after surgery, and postoperative pregnancy with post-
operative medication of 12 months or more, each proved to 
have a statistically significant association with the recurrence 
of endometrioma. Fifteen of the 134 women became preg-
nant after long-term medication, and endometrioma recur-
rence was observed in eight of those patients. Furthermore, 
five patients out of those eight patients diagnosed with 
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recurrent endometrioma had undergone cesarean section. 
In our study, the serum CA-125 level was higher in patients 
with recurrent endometrioma (median level 24.95 U/mL) 
compared with those without recurrent endometrioma 
(median level 15 U/mL). However, our univariate analysis 
showed that the recurrence risk was not significantly associ-
ated with the postoperative serum CA-125 level.
The relative risks of recurrence of endometrioma re-
vealed in the results of our univariate analysis shown in 
Table 2. In the univariate analysis, the risk of recurrence 
was significantly affected by weight, BMI, age at the time of 
surgery, diameter of the largest cyst, presence of dysmenor-
rhea, and postoperative pregnancy. 
The results of our multivariate logistic regression analy-
sis are presented in Table 3. According to the multivariate 
analysis, the significant factors that were associated with 
the recurrence of endometrioma were the body mass index 
(OR 1.153, 95% CI 1.003–1.326, P = 0.046), age at the time of 
surgery (OR 0.924, 95% CI 0.860–0.992, P = 0.029) and the 
presence of dysmenorrhea (OR 12.226, 95% CI 3.543–42.188, 
P < 0.0001). Across the entire cohort, the number of patients 
with recurrent endometrioma during the follow-up period 
gradually increased, reaching a total of 35 patients (26.1%) 
by the end of the 5-year postoperative period (Fig. 1).
DISCUSSION
Endometriosis has been systematically investigated 
for decades, but its treatment efficacy and recurrent risk 
factors are still only vaguely understood. The aim of this 
study was to explore the risk factors for the recurrence of 
endometrioma after long-term medical therapy and to find 
personalized patterns according to these risk factors. In this 
Table 1. Characteristics of patients with and without the recurrence of ovarian endometrioma and P values from the univariable analysis
Total (n = 134) Non-recurrent group (n = 99) Recurrent group (n = 35) P-value*
Weight [Kg] 57.44 (9.07) 56.23 (7.98) 60.84 (11.04) 0.028
Height [meter] 1.62 (0.05) 1.62 (0.05) 1.61 (0.05) 0.466
BMI [kg/m2] 22.01 (3.56) 21.48 (3.03) 23.49 (4.47) 0.018
Parity**, ‡ 0 100 (74.63) 71 (71.72) 29 (82.86) 0.447
1 14 (10.45) 13 (13.13) 1 (2.86)
2 18 (13.43) 13 (13.13) 5 (14.29)
3 1 (0.75) 1 (1.01) 0 (0.00)
4 1 (0.75) 1 (1.01) 0 (0.00)
Age at the time of surgery 34.23 (8.08) 35.28 (8.35) 31.26 (6.49) 0.011
Bilaterality** Left 40 (29.85) 30 (30.30) 10 (28.57) 0.640
Right 45 (33.58) 35 (35.35) 10 (28.57)
Both 49 (36.57) 34 (34.34) 15 (42.86)
CDS obliteration** No 62 (46.27) 43 (43.43) 19 (54.29) 0.268
Yes 72 (53.73) 56 (56.57) 16 (45.71)
Size** 0–3 cm 58 (43.28) 52 (52.53) 6 (17.14) < 0.001
> 3 cm 76 (56.72) 47 (47.47) 29 (82.86)
rASRM score*, † 44.50 [28.00, 84.00] 52.00 [31.00, 93.00] 41.00 (20.00, 76.00) 0.048
rASRM stage**, ‡ 1 6 (4.48) 3 (3.03) 3 (8.57) 0.017
2 5 (3.73) 1 (1.01) 4 (11.43)
3 47 (35.07) 38 (38.38) 9 (25.71)
4 76 (56.72) 57 (57.58) 19 (54.29)
Type of surgery** Laparotomy 53 (39.55) 42 (42.42) 11 (31.43) 0.253
Laparoscopy 81 (60.45) 57 (57.58) 24 (68.57)
Dysmenorrhea** No 111 (82.84) 93 (93.94) 18 (51.43) < 0.0001
Yes 23 (17.16) 6 (6.06) 17 (48.57)
Postoperative pregnancy**, ‡ No 119 (88.81) 92 (92.93) 27 (77.14) 0.024
Yes 15 (11.19) 7 (7.07) 8 (22.86)
Postoperative CA-125 (U/mL) *, † 16.07 [11.90, 29.43] 15.00 [10.73, 22.79] 24.95 (14.64,55.40) 0.007
Independent t-test or Wilcoxon rank-sum test (†) for continuous variables; Chi-square test or Fisher’s exact test (‡) for categorical variables; Values are mean (standard 
deviation); *, median (min-max); **, number [%]; BMI — body mass index; rASRM — revised American Society for Reproductive Medicine
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retrospective study, our univariate analysis showed that 
the weight, BMI, age at the time of surgery, the diameter of 
the cyst, the presence of dysmenorrhea, and postoperative 
pregnancy to be strongly associated with the recurrence of 
endometrioma. However, our multivariate analysis showed 
that the size of the cyst and postoperative pregnancy were 
not significantly associated with recurrent endometrioma. 
Some reports have indicated that the young age of 
patients was a risk factor [12, 20–22], while Parazzini et al. 
reported that higher recurrence rates were observed in older 
women [23]. The association between the patient’s age at 
surgery and endometrioma recurrence has been consist-
ently mentioned in previous studies [13, 20], and our study 
data showed that there is a statistically significant associa-
tion between younger-aged patients at the time of surgery 
and the risk of recurrent endometrioma. The reason for this 
increased recurrence rate is unclear, but we postulate that 
the higher circulation estrogens levels in younger women 
Table 2. Univariate logistic regression analyses of factors related to endometrioma recurrence
Predictors OR
95% CI
P-value
Lower Upper
Weight [Kg] 1.056 1.011 1.102 0.013
Height [meter] 0.971 0.899 1.050 0.463
BMI [kg/m2] 1.164 1.043 1.299 0.007
Parity (0) † 0.773 0.452 1.321 0.346
Age at the time of surgery 0.934 0.885 0.986 0.013
Extremity surgery 0.779 0.222 2.734 0.696
Abdominal surgery 0.539 0.112 2.592 0.441
Gynecologic surgery 1.463 0.616 3.475 0.389
Previous cesarean section 0.967 0.529 1.769 0.914
Previous surgeries 0.985 0.645 1.503 0.944
rASRM score (per 10 points) † 0.988 0.977 1.000 0.053
Bilaterality (Left) † Right 0.857 0.314 2.337 0.763
Both 1.324 0.518 3.384 0.558
CDS obliteration (No) † Yes 0.647 0.298 1.403 0.270
Size (0-3cm) † > 3 cm 5.348 2.040 14.015 0.001
rASRM stage (1) † 2 3.997 0.265 60.260 0.317
3 0.237 0.041 1.373 0.108
4 0.333 0.062 1.793 0.201
Type of surgery (Laparotomy) † Laparoscopy 1.607 0.710 3.640 0.255
Dysmenorrhea (No) † Yes 14.639 5.078 42.200 < 0.0001
Postoperative pregnancy (No) † Yes 3.894 1.294 11.715 0.016
Postoperative CA-125 [U/mL] 1.000 0.997 1.003 0.952
†, (reference); BMI — body mass index; rASRM — revised American Society for Reproductive Medicine
Table 3. Multivariate logistic regression analyses of factors related to endometrioma recurrence
Predictors level OR
95% CI
P-value *
Lower Upper
BMI 1.153 1.003 1.326 0.046
Age at the time of surgery 0.924 0.860 0.992 0.029
Size (0–3cm) † > 3 cm 2.845 0.940 8.608 0.064
Dysmenorrhea (No) † Yes 12.226 3.543 42.188 < 0.0001
Postoperative pregnancy (No) † Yes 3.334 0.887 12.527 0.075
†, (reference), BMI — body mass index
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at the time of the endometrioma diagnosis, may produce 
a more aggressive form of endometriosis, therefore, a form 
that is more likely to recur compared with the form of endo-
metriosis found in in older patients [11]. The patient’s age at 
surgery may well be a surrogate marker for the circulating 
estrogens levels in the patient [22]. However, in this study, 
we did not measure the estrogens levels and this postula-
tion should be confirmed with further prospective studies. 
While high BMI is cited as a risk factor for endometriosis 
by several authors [24, 25], the relation is far from clear. 
We too found that high BMI was a significant risk factor of 
recurrent endometrioma. Increased body weight may mask 
chronic symptoms such as pain, therefore resulting in less 
frequent diagnosis of endometriosis. Therefore, in such oc-
casions there is a possibility that endometriosis could be 
diagnosed at a more advanced stage. Also, the complete 
removal of ovarian endometrioma can prove challenging 
in obese patients. 
Several studies identified dysmenorrhea as a possi-
ble risk factor for endometrioma recurrence [26, 27]. Our 
study also showed an association between the presence of 
dysmenorrhea after surgery and recurrent endometrioma. 
Endometriotic lesions and adhesions may also cause deep 
pelvic pain associated with recurrent endometriosis [27]. In 
conclusion, postoperative dysmenorrhea could suggest the 
recurrence of endometrioma. 
It is clear from numerous reports that the prevalence 
of recurrent endometrioma varies according to whether 
there is a successful pregnancy after surgical treatment 
of the endometrioma [11, 20, 22, 28]. Koga et al. dem-
onstrated that patients with post-operative pregnancies 
had much lower rates of recurrence, which indicates that 
a subsequent pregnancy may have a protective effect in 
relation to the risk of recurrence of the endometrioma [13]. 
However, postoperative pregnancies did not prevent the 
recurrence of endometrioma in our study (OR, 3.334, 95% 
CI, 0.887–12.527, P-value = 0.075). Our results may be due 
to the limited number of cases we studied. Another pos-
sible explanation is iatrogenic spreading of endometrial 
tissue to the pelvic cavity during cesarean section [29, 30]. 
Five patients with successful pregnancies after their initial 
surgery, but who later had recurrent endometrioma, were 
diagnosed after cesarean sections. In addition, more con-
servative fertility-sparing surgery to minimize the loss of 
healthy ovarian tissue, should be a primary concern for 
treating infertile women with presumed endometriosis [31], 
as it is technically challenging for the surgeon to completely 
remove ovarian endometrioma in infertile women.
Several studies found an association between caesar-
ean section and endometriosis in the pelvic cavity [30, 32]. 
We performed a statistical analysis to compare the types of 
previous operations and their relations to endometrioma 
recurrence. The types of previous operations included ex-
tremity operations such as arm and leg fracture surgery, 
abdominal operations, and gynecologic operations other 
than endometriosis and/or cesarean section [30, 33]. How-
ever, in our study, there were no correlations between the 
recurrence of endometriosis and previous operations.
As previously discussed, two major risk factors of en-
dometrioma recurrence that were revealed in our study, 
a younger age at surgery and post-operative dysmenor-
rhea, could both be explained by theories of endometrioma 
recurrence. In younger patients, serum estrogen levels are 
relatively high, which could lead to further stimulation and 
development of endometrioma from retrograde menstrua-
tion after surgery [9]. Equally, on the other hand, postop-
erative dysmenorrhea could have been caused by residual 
lesions from previous surgery. However, to further clarify the 
underlying mechanism of endometrioma recurrence and 
its associated risk factors, additional studies are warranted.
The recurrence rate of endometrioma after primary 
surgery followed by postoperative medical treatment for 
18 months has been reported to be 19.1% after 2 years 
and 40%–50% after 5 years [34]. Several studies reported 
that the incidence of endometriosis recurrence after lap-
aroscopic surgery is 19–50% [13, 35]. We found that the 
estimated cumulative incidences of recurrence rate were 
1.5%, 9.7%, 13.4%, 17.2%, and 26.1% respectively, at 1, 2, 3, 
4, and 5 years after surgery. These relatively low recurrence 
rates may be due to long-term medical therapy and the 
recurrence definition applied in our study. Postoperative 
medical treatment is known to delay the recurrence, but 
not completely prevent it [36]. 
Our study has several limitations. The follow-up periods 
for some of the patients in our population were relatively 
short, and the study included a very small number of sub-
jects. Also, medical therapy was not identical for all patients, 
Figure 1. Estimated cumulative number of patients with a recurrence 
of ovarian endometrioma after laparoscopic cystectomy in Korean 
women who were treated with postoperative medical therapy
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which possibly influenced the recurrence rate. However, our 
study covered patients who were treated with long-term 
postoperative medical therapy for recurrence prevention. 
All study subjects received postoperative medical therapy 
for more than 12 months. Because current studies on endo-
metriosis treatment focus on its medical aspects, it would be 
meaningful to analyze the factors related to the recurrence 
rate in those endometriosis patients under a long-term pe-
riod of medical treatment. Furthermore, this retrospective 
study was designed to focus correlations between the risk 
factors of endometriosis recurrence, with less weight given 
to the underlying mechanism and causal relationships be-
tween each of the risk factors and its corresponding statistical 
results; so further studies regarding such issues are needed. 
Furthermore, we studied 18 potential risk factors to 
identify any clinical patterns in the study subjects. It is very 
important to predict the risk of recurrent endometrioma 
to determine postoperative treatment, and we believe our 
findings are especially helpful for counselling patients at 
high risk of recurrence. 
CONCLUSIONS
We concluded that dysmenorrhea after surgery, and 
a younger age at the time of surgery (odds ratio 12.226, 
p-value < 0.0001 and 0.924, p-value = 0.029, respectively) 
were risk factors that are associated with recurrent endo-
metrioma, despite long-term postoperative medication. 
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